Intuitive Surgical (ISRG) is back in focus after reporting second quarter results that exceeded analyst earnings and sales estimates, alongside new regulatory and AI related milestones across its robotic surgery ecosystem.

Despite the strong second quarter beat and new AI and ecosystem milestones, Intuitive Surgical’s 30 day share price return is down 17.65% and its year to date share price return is down 40.92%. The 3 year total shareholder return of 2.62% and 5 year total shareholder return of 1.49% point to relatively modest long term gains, indicating that momentum has clearly cooled.

If Intuitive Surgical’s recent pullback has you reassessing opportunities in surgical tech, this is a useful moment to scan other robotics focused stocks through the 33 robotics and automation stocks

For Intuitive Surgical, the sharp share price reset sits awkwardly next to solid recent earnings and an expanding robotics ecosystem. Are you seeing a business problem here, or mainly a swing in sentiment that changes how valuation stacks up next?

Most Popular Narrative: 47.3% Undervalued

Against Intuitive Surgical’s last close of $332.03, the most followed narrative points to a fair value of $630.48, suggesting a wide gap that the market is currently pricing very differently.

I have followed ISRG since 2003 when it was brought to the investing club I had just joined. I tried to analyze ISRG with the BetterInvesting SSG methodology that I had been introduced to and I could not get it in the buy zone. Wiser heads in the club prevailed and we started a position at around $48 a share and continued to add to the position. In 2005 ISRG was trading at over $200 a share and I was getting nervous. I convinced the club to place a trailing stop on ISRG. The price continued to increase and reached $393 a share. Then ISRG stock price started to drop and it got as low as $200 a share. Our trailing stop worked like a charm and we were sold out of the club position at just above $360 a share. I tried to convince the club to reinvest in ISRG at $200 a share and they decided not to, but I did. I describe it as riding the lightning. I have bought and sold ISRG at least twice since then and watched the share price increase to over $1000 a share twice before doing a 3 for 1 stock split. First in 2017 and then again in 2021. Did I mention no debt?

Want to understand why this narrative still lands on a fair value almost twice the current price? The core story leans on robust profit margins, a premium future earnings multiple and steady revenue expansion assumptions that stretch far beyond the recent pullback. Curious which growth and margin inputs are doing the heavy lifting in that $630.48 figure, and how they connect to Intuitive Surgical’s installed base and procedure trends?

Result: Fair Value of $630.48 (UNDERVALUED)

However, Intuitive Surgical’s narrative could be pressured if procedure growth slows or if hospitals delay new system purchases and instrument usage because of tighter capital budgets.

Another View on Intuitive Surgical’s valuation

The popular narrative points to Intuitive Surgical being undervalued, but the current P/E of 37.4x tells a different story. It sits above the US Medical Equipment industry at 26.5x, above peers at 27.3x, and above the 34.3x fair ratio that our model suggests the market could move toward.

That richer multiple may reflect quality and growth expectations. However, it also means there is less room for error if sentiment or forecasts shift again. Which signal do you put more weight on right now: the discounted fair value or the premium earnings multiple?

Next Steps

If this mix of strong results and a sharp pullback leaves you undecided, take a moment to move beyond headlines and weigh the data for yourself. To see what is driving optimism, start by checking the 3 key rewards.

Looking for more investment ideas beyond Intuitive Surgical?

If Intuitive Surgical has sharpened your interest in focused stock research, do not stop here. Fresh opportunities often appear where fewer investors are currently looking.

• Target potential mispricings across the market by scanning companies on compelling valuations using the 38 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with higher yields and supportable payouts through the 7 dividend fortresses.
• Prioritize resilience by filtering for companies with robust finances and durable fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.